Nektar Therapeutics Presents NKTR-255 at ASH
Nektar Therapeutics’ (NKTR) IL-15 agonist investigational candidate NKTR-255 presentations at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition have been promising. Positive data presented from Fred Hutchinson Cancer Research Center preclinical studies conducted in collaboration with researchers from the Dana-Farber Cancer Institute and more.
NKTR-255 is currently . . .
This content is for paid subscribers.
Today’s Highlights December 11, 2019